FLT3 D835

CI-VAR-00000570Explore in graph →ClinVar 16276 CIViC 437 rs121913488

Curated evidence

Evidence by cancer (13 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–13 of 13 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia12
FLT3 D835	Gilteritinib	Predictive	B	Supports Sensitivity Response	1	rejected	EID8333 In a Phase 1-2 trial of patients with relapsed / refractory AML, patients were enrolled in 7 dose-escalation or dose-expansion cohorts. Gilteritinib monotherapy was well tolerated, generated high resp… (full text at CIViC) PMID 28645776 · Perl et al., 2017 · Open in CIViC	civic
FLT3 D835	Ponatinib + QuizartinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID1036 An in-vitro saturation mutagenesis screen of 50 independently derived FLT3-ITD clones was performed to identify mutations that confer resistance to ponatinib. Mutations at 3 AL residues (D835 [n = 31]… (full text at CIViC) PMID 23430109 · Smith et al., 2013 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16276	Pathogenic	no assertion criteria provided	0	Acute lymphoid leukemia; Acute myeloid leukemia	somatic	2	Mar 30, 2018	clinvar

Myelodysplastic Syndrome1
FLT3 D835	(prognostic)	Prognostic	C	Supports Poor Outcome	2	accepted	EID8330 In a study of 82 newly diagnosed myelodysplastic syndrome (MDS) patients followed through to progression to acute myeloid leukemia (AML) (n =70), the incidence of FLT3 (ITD, TKD) and NRAS mutations at… (full text at CIViC) PMID 14737077 · Shih et al., 2004 · Open in CIViC	civic